Stock UMED UNITÉ DE FABRICATION DES MÉDICAMENTS S.A
Add to a list
To use this feature you must be a member
Log inSign up

Unité de Fabrication des Médicaments S.A Stock

Equities

UMED

TN0007720014

Pharmaceuticals

End-of-day quote Tunis
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
6.7 TND -0.74% Intraday chart for Unité de Fabrication des Médicaments S.A -5.90% -10.43%
2023 Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Half Year Ended June 30, 2023 CI
2023 Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Full Year Ended December 31, 2022 CI

Financials

Sales 2023 * 134M 42.97M Sales 2024 * 141M 45.21M Capitalization 214M 68.75M
Net income 2023 * 16M 5.13M Net income 2024 * 18M 5.77M EV / Sales 2023 * 2.06 x
Net Debt 2023 * 61.1M 19.59M Net Debt 2024 * 66.6M 21.36M EV / Sales 2024 * 1.99 x
P/E ratio 2023 *
11.6 x
P/E ratio 2024 *
10.8 x
Employees 572
Yield 2023 *
7.46%
Yield 2024 *
8.21%
Free-Float 29.98%
More Fundamentals * Assessed data

Chart Unité de Fabrication des Médicaments S.A

Dynamic Chart

Latest news about Unité de Fabrication des Médicaments S.A

Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Unité de Fabrication des Médicaments Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Unité De Fabrication Des Médicaments Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Ridha Charfeddine and others acquired 6.85% stake in Unité de Fabrication des Médicaments from SQM Frontier Africa Master Fund, Ltd., managed by SQM Frontier Management, LP. CI
Unite De Fabrication De Medicaments SA(BVMT:UMED) added to S&P Pan Arab Composite CI
Unite De Fabrication De Medicaments SA has completed an IPO in the amount of TND 43.22 million. CI
Unite De Fabrication De Medicaments SA has filed an IPO. CI
SQM Frontier Management, LP, Consortium Tuniso-Koweitien de Developpement, Blakeney Asset Management of Miles Morland Foundation, and two local investors acquired 83% stake in Unite De Fabrication De Medicaments SA from PROPARCO SA and The Abraaj Group. CI
More news

Press releases Unité de Fabrication des Médicaments S.A

ZCG-Backed Unimed Launches Telemedicine Solution to Further Enhance Technology Solutions for Maritime Medical Platform AQ
AM Best Comments on Credit Ratings of Union Medical Benefits Society Limited AQ
AM Best Places Credit Ratings of Accuro Health Insurance Society Limited Under Review With Developing Implications AQ
AM Best Affirms Credit Ratings of Union Medical Benefits Society Limited AQ
34 Pioneer Students of Nigeria's First Medical Varsity, UNIMED, Ondo, Inducted AQ
More press releases

News in other languages on Unité de Fabrication des Médicaments S.A

Unite de Fabrication des Medicaments S A : UNIMED - Communiqué de presse
Unite de Fabrication des Medicaments S A : UNIMED - Etats financiers semestriels au 30/06/2023
Unite de Fabrication des Medicaments S A : UNIMED - Indicateurs d'activité trimestriels au 30/06/2023
Unite de Fabrication des Medicaments S A : UNIMED - information post AGO du 02/06/2023
Unite de Fabrication des Medicaments S A : UNIMED - Paiement de dividendes
More news

Quotes and Performance

1 day-0.74%
1 week-5.90%
1 month-6.94%
3 months-4.96%
6 months-10.07%
Current year-10.43%
More quotes

Highs and lows

1 week
6.64
Extreme 6.64
7.10
1 month
6.64
Extreme 6.64
7.35
Current year
6.64
Extreme 6.64
7.56
1 year
6.64
Extreme 6.64
8.28
3 years
6.61
Extreme 6.61
8.28
5 years
6.61
Extreme 6.61
10.95
10 years
6.61
Extreme 6.61
11.40
More quotes

Managers and Directors - Unité de Fabrication des Médicaments S.A

Managers TitleAgeSince
Ridha Charfeddine CEO
 Chief Executive Officer - 88-12-31
Lotfi Charfeddine DFI
 Director of Finance/CFO - -
Imen Charfeddine CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Ridha Charfeddine CEO
 Chief Executive Officer - 88-12-31
Lotfi Charfeddine DFI
 Director of Finance/CFO - -
Salah Ben Turkia BRD
 Director/Board Member - 15-12-31
More insiders

Quotes

Date Price Change Volume
24-05-31 6.7 -0.74% 34,288
24-05-30 6.75 -.--% 43,978
24-05-29 6.75 -0.74% 9,870
24-05-28 6.8 -4.23% 29,791
24-05-27 7.1 -0.28% 2,182

End-of-day quote Tunis, May 30, 2024

More quotes

Company Profile

Unimed (Unité de Fabrication de Médicaments) is one of the leading pharmaceutical groups in Tunisia. The activity is organized around 2 families of products: - generic medicines: primarily infusion and inhalation products, ophthalmic products, injectable liquids and powders; - fashioned medicines: medicines manufactured for third parties.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Ratings for Unité de Fabrication des Médicaments S.A

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.7 TND
Average target price
12.1 TND
Spread / Average Target
+80.60%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
UNITÉ DE FABRICATION DES MÉDICAMENTS S.A Stock Unité de Fabrication des Médicaments S.A
-10.43% 68.73M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. UMED Stock